Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol
This study is testing a new gene-editing medicine called VERVE-102 to see if it is safe and helps lower bad cholesterol. It is designed for people who still need help lowering their cholesterol even with standard treatments.
You might be able to join if you have inherited high cholesterol from one parent or developed early heart disease. However, you cannot join if you have certain liver conditions, inherited high cholesterol from both parents, or take specific PCSK9 inhibitor medicines.
Participants will receive a single dose of the investigational medicine VERVE-102, which uses a special technology to target the liver and reduce cholesterol levels. The study team will closely monitor your safety and health throughout the process.
This study is currently recruiting participants at locations in Alabama, California, and Florida in the United States.
- 1Tests an investigational gene-editing medicine called VERVE-102 to lower bad cholesterol.
- 2Looking for adults with inherited high cholesterol or early-onset heart disease who need extra help lowering cholesterol.
- 3Currently recruiting patients at multiple medical centers in the United States.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.